Dialing down the toxic effects of radiation on cancer patients, Galera gets breakthrough status on Phase IIb data
A biotechnology company near Philadelphia — armed with data from a Phase IIb trial — just got breakthrough status from the FDA for a drug that might …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.